Ralinepag

Drug Profile

Ralinepag

Alternative Names: APD-811

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Class Acetic acids; Antihypertensives; Carbamates; Chlorobenzenes; Small molecules
  • Mechanism of Action Epoprostenol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pulmonary arterial hypertension

Most Recent Events

  • 14 Mar 2017 Arena Pharmaceuticals initiates enrolment in a phase I pharmacokinetics and pharmacodynamics trial for ralinepag in healthy volunteers
  • 07 Dec 2016 Pharmacokinetics data from phase I trials in Pulmonary arterial hypertension released by Arena Pharmaceuticals
  • 07 Dec 2016 Arena Pharmaceuticals completes enrolment in a phase II trial for Pulmonary arterial hypertension in US, Australia, Bulgaria, Czech Republic, Hungary, Poland, Serbia, Spain and Romania
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top